{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:04:25Z","timestamp":1773248665337,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Graft-versus-host disease (GVHD) is a major concern for patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Ruxolitinib has been proven effective in treating adult steroid-refractory GVHD; however, studies on pediatric patients are relatively scarce. Thus, this single-center study evaluated the efficacy and safety of ruxolitinib in pediatric patients with steroid-refractory GVHD. We retrospectively reviewed the data of patients aged\u2009&lt;\u200918 years who underwent allogeneic HSCT and received ruxolitinib treatment for either acute GVHD (aGVHD) or chronic GVHD (cGVHD) between 2018 and 2023. Data on the clinical response, concomitant and subsequent medications, adverse events, and outcomes were obtained through medical chart review. Sixteen patients were analyzed in this study: seven with aGVHD and nine with cGVHD. The overall response rate for the 16 patients was 81% (aGVHD, 86%; cGVHD, 77%). The overall survival rate was 56%: (aGVHD, 57%; cGVHD, 55%). For 11 patients with at least stable disease, steroid dosage could be reduced by at least 75%; however, corticosteroids were successfully tapered off in only six patients at the last follow-up. Among four patients with documented lung cGVHD, none experienced lung cGVHD progression at 1-year follow-up. Further, 50% of the patients experienced grade 3 or 4 neutropenia and\/or thrombocytopenia, and 56% had viral reactivation. Two patients discontinued ruxolitinib owing to adverse events. Ruxolitinib treatment for pediatric patients with aGVHD and cGVHD is associated with a high overall response rate, significant steroid-sparing effect, acceptable toxicity, and manageable adverse events. However, blood count and viral reactivation should be closely monitored during ruxolitinib use.<\/jats:p>","DOI":"10.1007\/s00277-025-06225-0","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T04:15:29Z","timestamp":1738642529000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Ruxolitinib for pediatric acute and chronic graft-versus-host disease: a single-center retrospective study of efficacy and safety"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4277-4501","authenticated-orcid":false,"given":"Chiao-Yu","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4461-9967","authenticated-orcid":false,"given":"Meng-Yao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1832-8509","authenticated-orcid":false,"given":"Hsiu-Hao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3598-7218","authenticated-orcid":false,"given":"Yung-Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Hsueh","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5773-3200","authenticated-orcid":false,"given":"Dong-Tsamn","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5833-7066","authenticated-orcid":false,"given":"Kai-Hsin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4562-6002","authenticated-orcid":false,"given":"Shu-Wei","family":"Chou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1483-0403","authenticated-orcid":false,"given":"Shiann-Tarng","family":"Jou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"key":"6225_CR1","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1080\/1744666X.2020.1740592","volume":"16","author":"H Ali","year":"2020","unstructured":"Ali H, Salhotra A, Modi B, Nakamura R (2020) Ruxolitinib for the treatment of graft-versus-host disease. Expert Rev Clin Immunol 16:347\u2013359. https:\/\/doi.org\/10.1080\/1744666X.2020.1740592","journal-title":"Expert Rev Clin Immunol"},{"key":"6225_CR2","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.bbmt.2012.04.005","volume":"18","author":"PJ Martin","year":"2012","unstructured":"Martin PJ, Rizzo JD, Wingard JR et al (2012) First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and marrow transplantation. Biol Blood Marrow Transpl 18:1150\u20131163. https:\/\/doi.org\/10.1016\/j.bbmt.2012.04.005","journal-title":"Biol Blood Marrow Transpl"},{"key":"6225_CR3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1710-1492-9-30","volume":"9","author":"D Liu","year":"2013","unstructured":"Liu D, Ahmet A, Ward L et al (2013) A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol 9:30. https:\/\/doi.org\/10.1186\/1710-1492-9-30","journal-title":"Allergy Asthma Clin Immunol"},{"key":"6225_CR4","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3390\/ph15030374","volume":"15","author":"A Marcuzzi","year":"2022","unstructured":"Marcuzzi A, Rimondi E, Melloni E et al (2022) New applications of JAK\/STAT inhibitors in Pediatrics: current use of Ruxolitinib. Pharmaceuticals (Basel) 15:374. https:\/\/doi.org\/10.3390\/ph15030374","journal-title":"Pharmaceuticals (Basel)"},{"key":"6225_CR5","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1182\/bloodadvances.2020002097","volume":"4","author":"R Zeiser","year":"2020","unstructured":"Zeiser R, Socie G (2020) The development of ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. Blood Adv 4:3789\u20133794. https:\/\/doi.org\/10.1182\/bloodadvances.2020002097","journal-title":"Blood Adv"},{"key":"6225_CR6","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","volume":"382","author":"R Zeiser","year":"2020","unstructured":"Zeiser R, von Bubnoff N, Butler J et al (2020) Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med 382:1800\u20131810. https:\/\/doi.org\/10.1056\/NEJMoa1917635","journal-title":"N Engl J Med"},{"key":"6225_CR7","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2033122","volume":"385","author":"R Zeiser","year":"2021","unstructured":"Zeiser R, Polverelli N, Ram R et al (2021) Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. N Engl J Med 385:228\u2013238. https:\/\/doi.org\/10.1056\/NEJMoa2033122","journal-title":"N Engl J Med"},{"key":"6225_CR8","doi-asserted-by":"publisher","unstructured":"Ball L, Egeler R (2008) Acute GvHD: pathogenesis and classification. Bone Marrow Transpl 41. https:\/\/doi.org\/10.1038\/bmt.2008.56. S58-S64","DOI":"10.1038\/bmt.2008.56"},{"key":"6225_CR9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2016-07-686642","volume":"129","author":"SJ Lee","year":"2017","unstructured":"Lee SJ (2017) Classification systems for chronic graft-versus-host disease. Blood 129:30\u201337. https:\/\/doi.org\/10.1182\/blood-2016-07-686642","journal-title":"Blood"},{"key":"6225_CR10","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1182\/blood-2022-155708","volume":"140","author":"F Locatelli","year":"2022","unstructured":"Locatelli F, Kang HJ, Bruno B et al (2022) Ruxolitinib in pediatric patients with treatment-na\u00efve or steroid-refractory acute graft-versus-host disease: primary findings from the phase I\/II REACH4 study. Blood 140:1376\u20131378. https:\/\/doi.org\/10.1182\/blood-2022-155708","journal-title":"Blood"},{"key":"6225_CR11","doi-asserted-by":"publisher","first-page":"e580","DOI":"10.1016\/S2352-3026(24)00174-1","volume":"11","author":"F Locatelli","year":"2024","unstructured":"Locatelli F, Antmen B, Kang HJ et al (2024) Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study. Lancet Haematol 11:e580\u2013e592. https:\/\/doi.org\/10.1016\/S2352-3026(24)00174-1","journal-title":"Lancet Haematol"},{"key":"6225_CR12","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1182\/blood-2009-12-258442","volume":"115","author":"ML MacMillan","year":"2010","unstructured":"MacMillan ML, DeFor TE, Weisdorf DJ (2010) The best endpoint for acute GVHD treatment trials. Blood 115:5412\u20135417. https:\/\/doi.org\/10.1182\/blood-2009-12-258442","journal-title":"Blood"},{"key":"6225_CR13","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2217\/imt-2017-0156","volume":"10","author":"M Jagasia","year":"2018","unstructured":"Jagasia M, Zeiser R, Arbushites M, Delaite P, Gadbaw B, Bubnoff NV (2018) Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials. Immunotherapy 10:391\u2013402. https:\/\/doi.org\/10.2217\/imt-2017-0156","journal-title":"Immunotherapy"},{"key":"6225_CR14","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/s41409-022-01741-3","volume":"57","author":"F Biavasco","year":"2022","unstructured":"Biavasco F, Ihorst G, Wasch R et al (2022) Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tract. Bone Marrow Transpl 57:1500\u20131506. https:\/\/doi.org\/10.1038\/s41409-022-01741-3","journal-title":"Bone Marrow Transpl"},{"key":"6225_CR15","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/s41409-024-02252-z","volume":"59","author":"F Baccelli","year":"2024","unstructured":"Baccelli F, Gottardi F, Muratore E et al (2024) Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children: a systematic review and individual patient data meta-analysis. Bone Marrow Transpl 59:765\u2013776. https:\/\/doi.org\/10.1038\/s41409-024-02252-z","journal-title":"Bone Marrow Transpl"},{"key":"6225_CR16","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1038\/s41409-019-0450-3","volume":"54","author":"M Schoettler","year":"2019","unstructured":"Schoettler M, Duncan C, Lehmann L, Furutani E, Subramaniam M, Margossian S (2019) Ruxolitinib is an effective steroid sparing agent in children with steroid refractory\/dependent bronchiolitis obliterans syndrome after allogenic hematopoietic cell transplantation. Bone Marrow Transpl 54:1158\u20131160. https:\/\/doi.org\/10.1038\/s41409-019-0450-3","journal-title":"Bone Marrow Transpl"},{"key":"6225_CR17","doi-asserted-by":"publisher","first-page":"916472","DOI":"10.3389\/fphar.2022.916472","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, Zhao X, Shen Y et al (2022) Ruxolitinib as an effective and steroid-sparing first-line treatment in newly diagnosed BOS patients after hematopoietic stem cell transplantation. Front Pharmacol 13:916472. https:\/\/doi.org\/10.3389\/fphar.2022.916472","journal-title":"Front Pharmacol"},{"key":"6225_CR18","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1634\/theoncologist.2019-0627","volume":"25","author":"D Przepiorka","year":"2020","unstructured":"Przepiorka D, Luo L, Subramaniam S et al (2020) FDA approval Summary: Ruxolitinib for treatment of steroid-refractory Acute graft-versus-host disease. Oncologist 25:e328\u2013e334. https:\/\/doi.org\/10.1634\/theoncologist.2019-0627","journal-title":"Oncologist"},{"key":"6225_CR19","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.bbmt.2017.03.029","volume":"23","author":"P Khandelwal","year":"2017","unstructured":"Khandelwal P, Teusink-Cross A, Davies SM et al (2017) Ruxolitinib as salvage therapy in steroid-refractory acute graft-versus-host disease in pediatric hematopoietic stem cell transplant patients. Biol Blood Marrow Transpl 23:1122\u20131127. https:\/\/doi.org\/10.1016\/j.bbmt.2017.03.029","journal-title":"Biol Blood Marrow Transpl"},{"key":"6225_CR20","doi-asserted-by":"publisher","first-page":"107005","DOI":"10.1016\/j.leukres.2022.107005","volume":"125","author":"D Lebon","year":"2023","unstructured":"Lebon D, Dujardin A, Caulier A et al (2023) Ruxolitinib-induced reactivation of cytomegalovirus and Epstein-Barr virus in graft-versus-host disease. Leuk Res 125:107005. https:\/\/doi.org\/10.1016\/j.leukres.2022.107005","journal-title":"Leuk Res"},{"key":"6225_CR21","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s40262-023-01225-7","volume":"62","author":"TYJ Appeldoorn","year":"2023","unstructured":"Appeldoorn TYJ, Munnink THO, Morsink LM, Hooge MNL, Touw DJ (2023) Pharmacokinetics and pharmacodynamics of ruxolitinib: a review. Clin Pharmacokinet 62:559\u2013571. https:\/\/doi.org\/10.1007\/s40262-023-01225-7","journal-title":"Clin Pharmacokinet"},{"key":"6225_CR22","doi-asserted-by":"publisher","unstructured":"Cook E, Dong M, Chiang SCC et al (2024) Ruxolitinib pharmacokinetics and pharmacodynamics in children with acute and chronic graft-versus-host disease. Transpl Cell Ther 30. https:\/\/doi.org\/10.1016\/j.jtct.2024.02.018.:528 e1-528 e12","DOI":"10.1016\/j.jtct.2024.02.018"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06225-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06225-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06225-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T04:15:32Z","timestamp":1738642532000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06225-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":22,"alternative-id":["6225"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06225-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]},"assertion":[{"value":"30 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. This study has been approved by the Institutional Review Board of National Taiwan University Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The patient\u2019s consent was waived for retrospective study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}